The U.S. Food and Drug Administration (FDA) has agreed to review Pharming’s application to get Ruconest (conestat alfa) approved for the routine prevention of swelling attacks caused by hereditary angioedema (HAE). The therapy already is approved for the acute treatment of swelling attacks in adults and adolescents with…
News
Recent Posts
- Infant’s recurrent swelling shows how angioedema can mimic lymphedema
- Woman on HAE treatment early in pregnancy delivers healthy baby
- Bruise-like facial swelling leads to HAE diagnosis in 7-year-old girl
- Better understanding the HAE attack triggers in our lives
- Informed doctors help patients navigate HAE treatment options